FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000846576> ?p ?o ?g. }

• W2000846576 endingPage "1595" @default.
• W2000846576 startingPage "1589" @default.
• W2000846576 abstract "Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta.BackgroundFabry disease is an X-linked inherited disorder that is caused by excessive lysosomal globotriaosylceramide (CTH) storage due to a deficiency in α-galactosidase A (α-Gal A). Two recombinant enzyme preparations have been approved as treatment modality. We studied emergence and properties of α-Gal A antibodies in treated patients.MethodsDuring the first 6 to 12 months of intravenous administration of recombinant enzymes (rh-α-Gal A) formation of antibodies was studied in 18 adult Fabry patients (two females).ResultsThe female patients did not develop detectable amounts of antibodies following enzyme therapy. After 6 months of treatment with either agalsidase alpha or beta, 11/16 male patients showed high titers of immunoglobulin G (IgG) antibodies that cross-react in vitro similarly with both recombinant enzymes. The anti–rh-α-Gal A IgG neutralizes rh-α-Gal A activity in vitro for 65% to 95%. During infusion with rh-α-Gal A, circulating enzyme-antibody complexes are formed and these complexes are taken up by leukocytes in the peripheral blood. After 6 months of treatment all IgG-negative patients showed a significant (P < 0.01) reduction of urinary CTH (1890 ± 797 to 603 ± 291 nmol CTH/24hr urine), compared to IgG-positive patients (mean increase from 2535 ± 988 to 2723 ± 1212), suggesting a negative effect of circulating antibodies on renal tubular CTH clearance.ConclusionEmergence of antibodies with in vivo neutralizing capacities is frequently encountered in treated Fabry disease patients. Complete cross-reactivity of these antibodies suggests that it is unlikely that switching from one to the other recombinant protein prevents the immune response and related effects. Further studies on the clinical implications of α-Gal A antibodies are essential. Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Fabry disease is an X-linked inherited disorder that is caused by excessive lysosomal globotriaosylceramide (CTH) storage due to a deficiency in α-galactosidase A (α-Gal A). Two recombinant enzyme preparations have been approved as treatment modality. We studied emergence and properties of α-Gal A antibodies in treated patients. During the first 6 to 12 months of intravenous administration of recombinant enzymes (rh-α-Gal A) formation of antibodies was studied in 18 adult Fabry patients (two females). The female patients did not develop detectable amounts of antibodies following enzyme therapy. After 6 months of treatment with either agalsidase alpha or beta, 11/16 male patients showed high titers of immunoglobulin G (IgG) antibodies that cross-react in vitro similarly with both recombinant enzymes. The anti–rh-α-Gal A IgG neutralizes rh-α-Gal A activity in vitro for 65% to 95%. During infusion with rh-α-Gal A, circulating enzyme-antibody complexes are formed and these complexes are taken up by leukocytes in the peripheral blood. After 6 months of treatment all IgG-negative patients showed a significant (P < 0.01) reduction of urinary CTH (1890 ± 797 to 603 ± 291 nmol CTH/24hr urine), compared to IgG-positive patients (mean increase from 2535 ± 988 to 2723 ± 1212), suggesting a negative effect of circulating antibodies on renal tubular CTH clearance. Emergence of antibodies with in vivo neutralizing capacities is frequently encountered in treated Fabry disease patients. Complete cross-reactivity of these antibodies suggests that it is unlikely that switching from one to the other recombinant protein prevents the immune response and related effects. Further studies on the clinical implications of α-Gal A antibodies are essential." @default.
• W2000846576 created "2016-06-24" @default.
• W2000846576 creator A5008321998 @default.
• W2000846576 creator A5008373042 @default.
• W2000846576 creator A5013935159 @default.
• W2000846576 creator A5024669037 @default.
• W2000846576 creator A5063220459 @default.
• W2000846576 date "2004-10-01" @default.
• W2000846576 modified "2023-09-30" @default.
• W2000846576 title "Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta" @default.
• W2000846576 cites W1971873142 @default.
• W2000846576 cites W2019308804 @default.
• W2000846576 cites W2022356406 @default.
• W2000846576 cites W2030054541 @default.
• W2000846576 cites W2040721946 @default.
• W2000846576 cites W2086437884 @default.
• W2000846576 cites W2091164561 @default.
• W2000846576 cites W2103540959 @default.
• W2000846576 cites W2120445861 @default.
• W2000846576 cites W2134197747 @default.
• W2000846576 cites W2168526937 @default.
• W2000846576 cites W22151467 @default.
• W2000846576 cites W2312413018 @default.
• W2000846576 cites W2313827278 @default.
• W2000846576 cites W2322128806 @default.
• W2000846576 cites W2337290468 @default.
• W2000846576 cites W2730938425 @default.
• W2000846576 doi "https://doi.org/10.1111/j.1523-1755.2004.00924.x" @default.
• W2000846576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15458455" @default.
• W2000846576 hasPublicationYear "2004" @default.
• W2000846576 type Work @default.
• W2000846576 sameAs 2000846576 @default.
• W2000846576 citedByCount "232" @default.
• W2000846576 countsByYear W20008465762012 @default.
• W2000846576 countsByYear W20008465762013 @default.
• W2000846576 countsByYear W20008465762014 @default.
• W2000846576 countsByYear W20008465762015 @default.
• W2000846576 countsByYear W20008465762016 @default.
• W2000846576 countsByYear W20008465762017 @default.
• W2000846576 countsByYear W20008465762018 @default.
• W2000846576 countsByYear W20008465762019 @default.
• W2000846576 countsByYear W20008465762020 @default.
• W2000846576 countsByYear W20008465762021 @default.
• W2000846576 countsByYear W20008465762022 @default.
• W2000846576 countsByYear W20008465762023 @default.
• W2000846576 crossrefType "journal-article" @default.
• W2000846576 hasAuthorship W2000846576A5008321998 @default.
• W2000846576 hasAuthorship W2000846576A5008373042 @default.
• W2000846576 hasAuthorship W2000846576A5013935159 @default.
• W2000846576 hasAuthorship W2000846576A5024669037 @default.
• W2000846576 hasAuthorship W2000846576A5063220459 @default.
• W2000846576 hasBestOaLocation W20008465761 @default.
• W2000846576 hasConcept C104317684 @default.
• W2000846576 hasConcept C126322002 @default.
• W2000846576 hasConcept C134018914 @default.
• W2000846576 hasConcept C150903083 @default.
• W2000846576 hasConcept C159654299 @default.
• W2000846576 hasConcept C181199279 @default.
• W2000846576 hasConcept C185592680 @default.
• W2000846576 hasConcept C203014093 @default.
• W2000846576 hasConcept C207001950 @default.
• W2000846576 hasConcept C2776788019 @default.
• W2000846576 hasConcept C2777404818 @default.
• W2000846576 hasConcept C2777687718 @default.
• W2000846576 hasConcept C2779134260 @default.
• W2000846576 hasConcept C2779969927 @default.
• W2000846576 hasConcept C32611913 @default.
• W2000846576 hasConcept C40767141 @default.
• W2000846576 hasConcept C55493867 @default.
• W2000846576 hasConcept C71924100 @default.
• W2000846576 hasConcept C86803240 @default.
• W2000846576 hasConceptScore W2000846576C104317684 @default.
• W2000846576 hasConceptScore W2000846576C126322002 @default.
• W2000846576 hasConceptScore W2000846576C134018914 @default.
• W2000846576 hasConceptScore W2000846576C150903083 @default.
• W2000846576 hasConceptScore W2000846576C159654299 @default.
• W2000846576 hasConceptScore W2000846576C181199279 @default.
• W2000846576 hasConceptScore W2000846576C185592680 @default.
• W2000846576 hasConceptScore W2000846576C203014093 @default.
• W2000846576 hasConceptScore W2000846576C207001950 @default.
• W2000846576 hasConceptScore W2000846576C2776788019 @default.
• W2000846576 hasConceptScore W2000846576C2777404818 @default.
• W2000846576 hasConceptScore W2000846576C2777687718 @default.
• W2000846576 hasConceptScore W2000846576C2779134260 @default.
• W2000846576 hasConceptScore W2000846576C2779969927 @default.
• W2000846576 hasConceptScore W2000846576C32611913 @default.
• W2000846576 hasConceptScore W2000846576C40767141 @default.
• W2000846576 hasConceptScore W2000846576C55493867 @default.
• W2000846576 hasConceptScore W2000846576C71924100 @default.
• W2000846576 hasConceptScore W2000846576C86803240 @default.
• W2000846576 hasIssue "4" @default.
• W2000846576 hasLocation W20008465761 @default.
• W2000846576 hasLocation W20008465762 @default.
• W2000846576 hasOpenAccess W2000846576 @default.
• W2000846576 hasPrimaryLocation W20008465761 @default.
• W2000846576 hasRelatedWork W186628991 @default.
• W2000846576 hasRelatedWork W2000846576 @default.
• W2000846576 hasRelatedWork W2012825594 @default.

• next